Vice President / Executive Director – Corporate Communications, Product Communications, Global Franchise Strategy, or New Product Commercialization

Talent Profile: Executive Leader, Global Biopharmaceutical Communications & Franchise Strategy

This high-performing executive brings over 15 years of dual commercial and communications leadership within the biopharmaceutical sector, specializing in Central Nervous System (CNS) and Women’s Health. They possess a rare and highly sought-after blend of technical expertise: the ability to translate dense, highly technical scientific data into powerful commercial narratives that drive blockbuster market adoption, clear complex regulatory hurdles, and manage high-stakes reputation risks.

As a strategic "connector" across Commercial, Medical, Regulatory, and Investor Relations, this leader has a proven track record of aligning multi-billion-dollar global alliances around a unified product story to maximize long-term asset value.

Key Functional Expertise

• First-in-Class & Late-Stage Launch Leadership: Designed and executed integrated communication models for multiple first-in-class, breakthrough therapies from Phase 2/3 through FDA approval and market creation.

  
  

• Global Alliance & Cross-Functional Orchestration: Extensive experience managing complex co-promotion communications and cross-continental stakeholder alignment (including major US/Japan corporate parent relationships).

  
  

• Scientific Narrative & Clinical Positioning: Expert at developing Target Product Profiles (TPPs), disease-state education campaigns, and patient-centric messaging that dismantles market access barriers and clinical stigma.

  
  

• Crisis Communications & Reputation Management: A trusted advisor in highly scrutinized environments, having successfully managed communication strategies for FDA Advisory Committees, Warning Letters, patent litigation, and product recalls.

  
  

Major Career Milestones & Impact

• Orchestrated Market Creation for a Blockbuster CNS Therapy: Partnered with program leadership pre-launch to build an integrated communications ecosystem for a revolutionary psychiatric treatment, generating over 1 billion earned media and social impressions post-approval.

  
  

• Accelerated Time-to-Market Via Regulatory Strategy: Served as commercial lead for a prominent pipeline asset, playing a key role in securing FDA acceptance of Phase 2 data as pivotal—completely eliminating the need for Phase 3 trials and slashing years off development costs.

  
  

• Flawless Product Launch & Transition Execution: Led the integrated product narrative and a patient-centric formulation redesign for a flagship women’s health product, securing a first-cycle FDA approval and driving the brand to $120M+ in peak annual sales.

  
  

• Navigated High-Stakes FDA Milestones: Directed the scientific narrative, communication scenario planning, and advocacy strategy for a high-profile FDA Advisory Committee review, as well as managing complex transdermal product launches during global supply chain disruptions.